Pictet Asset Management (Switzerland)’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$73.9M Buy
1,480,747
+810,663
+121% +$38.4M 0.09% 238
2023
Q1
$25.1M Buy
670,084
+3,617
+0.5% +$153K 0.03% 413
2022
Q4
$32M Buy
+666,467
New +$26.2M 0.05% 343

Other funds holding PCVX

Pictet Asset Management (Switzerland)'s PCVX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Vaxcyte (PCVX) stake by 121% in Q2 2023, buying an estimated $38.4M and bringing the position to 1,480,747 shares worth $73.9M. The position accounts for 0.09% of the portfolio, ranked #238.

Pictet Asset Management (Switzerland) first reported a position in PCVX in Q4 2022 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 1,480,747 shares of Vaxcyte worth $73.9M as of Q2 2023.
  • Pictet Asset Management (Switzerland) bought 810,663 Vaxcyte shares in Q2 2023, an estimated $38.4M.
  • Vaxcyte made up 0.09% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #238 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Vaxcyte in Q4 2022 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.